- Home
- TDS vs PCVX Comparison
TDS vs PCVX Comparison
Compare TDS & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDS
- PCVX
- Stock Information
- Founded
- TDS 1968
- PCVX 2013
- Country
- TDS United States
- PCVX United States
- Employees
- TDS N/A
- PCVX N/A
- Industry
- TDS Telecommunications Equipment
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- TDS Telecommunications
- PCVX Health Care
- Exchange
- TDS Nasdaq
- PCVX Nasdaq
- Market Cap
- TDS 4.4B
- PCVX 4.0B
- IPO Year
- TDS N/A
- PCVX 2020
- Fundamental
- Price
- TDS $39.11
- PCVX $43.85
- Analyst Decision
- TDS Buy
- PCVX Strong Buy
- Analyst Count
- TDS 2
- PCVX 8
- Target Price
- TDS $52.00
- PCVX $114.17
- AVG Volume (30 Days)
- TDS 729.3K
- PCVX 1.7M
- Earning Date
- TDS 11-07-2025
- PCVX 11-05-2025
- Dividend Yield
- TDS 0.41%
- PCVX N/A
- EPS Growth
- TDS N/A
- PCVX N/A
- EPS
- TDS N/A
- PCVX N/A
- Revenue
- TDS $4,805,000,000.00
- PCVX N/A
- Revenue This Year
- TDS N/A
- PCVX N/A
- Revenue Next Year
- TDS $0.29
- PCVX N/A
- P/E Ratio
- TDS N/A
- PCVX N/A
- Revenue Growth
- TDS N/A
- PCVX N/A
- 52 Week Low
- TDS $26.95
- PCVX $27.66
- 52 Week High
- TDS $42.74
- PCVX $116.00
- Technical
- Relative Strength Index (RSI)
- TDS 53.50
- PCVX 62.86
- Support Level
- TDS $38.76
- PCVX $41.24
- Resistance Level
- TDS $40.57
- PCVX $45.50
- Average True Range (ATR)
- TDS 0.85
- PCVX 1.59
- MACD
- TDS 0.06
- PCVX -0.22
- Stochastic Oscillator
- TDS 48.40
- PCVX 61.27
About TDS Telephone and Data Systems Inc.
Telephone and Data Systems Inc is a diversified telecommunications operator that provides mobile, telephone, and broadband services. The company's segments include UScellular Wireless, UScellular Towers, and TDS Telecom. It generates maximum revenue from the UScellular Wireless segment.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.